ID   KPCD1_HUMAN             Reviewed;         912 AA.
AC   Q15139; A6NL64; B2RAF6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 2.
DT   10-MAY-2017, entry version 177.
DE   RecName: Full=Serine/threonine-protein kinase D1;
DE            EC=2.7.11.13;
DE   AltName: Full=Protein kinase C mu type;
DE   AltName: Full=Protein kinase D;
DE   AltName: Full=nPKC-D1;
DE   AltName: Full=nPKC-mu;
GN   Name=PRKD1; Synonyms=PKD, PKD1, PRKCM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8119958;
RA   Johannes F.-J., Prestle J., Eis S., Oberhagemann P., Pfizenmaier K.;
RT   "PKCmu is a novel, atypical member of the protein kinase C family.";
RL   J. Biol. Chem. 269:6140-6148(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   FUNCTION IN EGFR PHOSPHORYLATION.
RX   PubMed=10523301; DOI=10.1093/emboj/18.20.5567;
RA   Bagowski C.P., Stein-Gerlach M., Choidas A., Ullrich A.;
RT   "Cell-type specific phosphorylation of threonines T654 and T669 by PKD
RT   defines the signal capacity of the EGF receptor.";
RL   EMBO J. 18:5567-5576(1999).
RN   [6]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=10764790; DOI=10.1074/jbc.M002266200;
RA   Endo K., Oki E., Biedermann V., Kojima H., Yoshida K., Johannes F.J.,
RA   Kufe D., Datta R.;
RT   "Proteolytic cleavage and activation of protein kinase C [micro] by
RT   caspase-3 in the apoptotic response of cells to 1-beta -D-
RT   arabinofuranosylcytosine and other genotoxic agents.";
RL   J. Biol. Chem. 275:18476-18481(2000).
RN   [7]
RP   INTERACTION WITH ADAP1.
RX   PubMed=12893243; DOI=10.1016/S0006-291X(03)01187-2;
RA   Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D.,
RA   Wakefield R.I.D., Johannes F.-J., Aitken A.;
RT   "Centaurin-alpha(1) associates with and is phosphorylated by isoforms
RT   of protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 307:459-465(2003).
RN   [8]
RP   FUNCTION IN CELL SURVIVAL.
RX   PubMed=12505989; DOI=10.1093/emboj/cdg009;
RA   Storz P., Toker A.;
RT   "Protein kinase D mediates a stress-induced NF-kappaB activation and
RT   survival pathway.";
RL   EMBO J. 22:109-120(2003).
RN   [9]
RP   FUNCTION, ENZYME REGULATION, PHOSPHORYLATION AT TYR-432; TYR-463 AND
RP   TYR-502, AND MUTAGENESIS OF TYR-432; TYR-463; TYR-502 AND LYS-612.
RX   PubMed=12637538; DOI=10.1074/jbc.M213224200;
RA   Storz P., Doppler H., Johannes F.J., Toker A.;
RT   "Tyrosine phosphorylation of protein kinase D in the pleckstrin
RT   homology domain leads to activation.";
RL   J. Biol. Chem. 278:17969-17976(2003).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF TRPV1.
RX   PubMed=15471852; DOI=10.1074/jbc.M410331200;
RA   Wang Y., Kedei N., Wang M., Wang Q.J., Huppler A.R., Toth A., Tran R.,
RA   Blumberg P.M.;
RT   "Interaction between protein kinase Cmu and the vanilloid receptor
RT   type 1.";
RL   J. Biol. Chem. 279:53674-53682(2004).
RN   [11]
RP   PHOSPHORYLATION AT TYR-463; SER-738 AND SER-742.
RX   PubMed=15024053; DOI=10.1128/MCB.24.7.2614-2626.2004;
RA   Storz P., Doppler H., Toker A.;
RT   "Protein kinase Cdelta selectively regulates protein kinase D-
RT   dependent activation of NF-kappaB in oxidative stress signaling.";
RL   Mol. Cell. Biol. 24:2614-2626(2004).
RN   [12]
RP   PHOSPHORYLATION BY DAPK1, INTERACTION WITH DAPK1, PHOSPHORYLATION AT
RP   SER-910, AND ENZYME REGULATION.
RX   PubMed=17703233; DOI=10.1038/sj.cdd.4402212;
RA   Eisenberg-Lerner A., Kimchi A.;
RT   "DAP kinase regulates JNK signaling by binding and activating protein
RT   kinase D under oxidative stress.";
RL   Cell Death Differ. 14:1908-1915(2007).
RN   [13]
RP   PHOSPHORYLATION AT TYR-95.
RX   PubMed=17804414; DOI=10.1074/jbc.M703584200;
RA   Doppler H., Storz P.;
RT   "A novel tyrosine phosphorylation site in protein kinase D contributes
RT   to oxidative stress-mediated activation.";
RL   J. Biol. Chem. 282:31873-31881(2007).
RN   [14]
RP   FUNCTION IN INNATE IMMUNITY.
RX   PubMed=17442957; DOI=10.4049/jimmunol.178.9.5735;
RA   Ivison S.M., Graham N.R., Bernales C.Q., Kifayet A., Ng N.,
RA   Shobab L.A., Steiner T.S.;
RT   "Protein kinase D interaction with TLR5 is required for inflammatory
RT   signaling in response to bacterial flagellin.";
RL   J. Immunol. 178:5735-5743(2007).
RN   [15]
RP   ENZYME REGULATION, PHORBOL-ESTER BINDING, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF PRO-157 AND PRO-281.
RX   PubMed=18076381; DOI=10.1042/BJ20071334;
RA   Chen J., Deng F., Li J., Wang Q.J.;
RT   "Selective binding of phorbol esters and diacylglycerol by individual
RT   C1 domains of the PKD family.";
RL   Biochem. J. 411:333-342(2008).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF HDAC5, AND FUNCTION IN ANGIOGENESIS.
RX   PubMed=18332134; DOI=10.1074/jbc.M800264200;
RA   Ha C.H., Wang W., Jhun B.S., Wong C., Hausser A., Pfizenmaier K.,
RA   McKinsey T.A., Olson E.N., Jin Z.G.;
RT   "Protein kinase D-dependent phosphorylation and nuclear export of
RT   histone deacetylase 5 mediates vascular endothelial growth factor-
RT   induced gene expression and angiogenesis.";
RL   J. Biol. Chem. 283:14590-14599(2008).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF HDAC7.
RX   PubMed=18509061; DOI=10.1073/pnas.0802857105;
RA   Wang S., Li X., Parra M., Verdin E., Bassel-Duby R., Olson E.N.;
RT   "Control of endothelial cell proliferation and migration by VEGF
RT   signaling to histone deacetylase 7.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:7738-7743(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION AT SER-397 AND SER-401, INTERACTION WITH MAPK13, AND
RP   FUNCTION.
RX   PubMed=19135240; DOI=10.1016/j.cell.2008.11.018;
RA   Sumara G., Formentini I., Collins S., Sumara I., Windak R.,
RA   Bodenmiller B., Ramracheya R., Caille D., Jiang H., Platt K.A.,
RA   Meda P., Aebersold R., Rorsman P., Ricci R.;
RT   "Regulation of PKD by the MAPK p38delta in insulin secretion and
RT   glucose homeostasis.";
RL   Cell 136:235-248(2009).
RN   [20]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=19211839; DOI=10.1091/mbc.E08-09-0957;
RA   Czoendoer K., Ellwanger K., Fuchs Y.F., Lutz S., Gulyas M.,
RA   Mansuy I.M., Hausser A., Pfizenmaier K., Schlett K.;
RT   "Protein kinase D controls the integrity of Golgi apparatus and the
RT   maintenance of dendritic arborization in hippocampal neurons.";
RL   Mol. Biol. Cell 20:2108-2120(2009).
RN   [21]
RP   REVIEW ON FUNCTION IN TRAFFICKING.
RX   PubMed=11978539; DOI=10.1016/S0962-8924(02)02262-6;
RA   Van Lint J., Rykx A., Maeda Y., Vantus T., Sturany S., Malhotra V.,
RA   Vandenheede J.R., Seufferlein T.;
RT   "Protein kinase D: an intracellular traffic regulator on the move.";
RL   Trends Cell Biol. 12:193-200(2002).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=15701647; DOI=10.1074/jbc.R500002200;
RA   Rozengurt E., Rey O., Waldron R.T.;
RT   "Protein kinase D signaling.";
RL   J. Biol. Chem. 280:13205-13208(2005).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=18239146; DOI=10.1161/CIRCRESAHA.107.168211;
RA   Avkiran M., Rowland A.J., Cuello F., Haworth R.S.;
RT   "Protein kinase d in the cardiovascular system: emerging roles in
RT   health and disease.";
RL   Circ. Res. 102:157-163(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-345; SER-448
RP   AND SER-473, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [25]
RP   REVIEW ON FUNCTION IN ANGIOGENESIS.
RX   PubMed=19655095; DOI=10.1007/s10059-009-0109-9;
RA   Ha C.H., Jin Z.G.;
RT   "Protein kinase D1, a new molecular player in VEGF signaling and
RT   angiogenesis.";
RL   Mol. Cells 28:1-5(2009).
RN   [26]
RP   REVIEW ON FUNCTION.
RX   PubMed=21357900; DOI=10.1152/physiol.00037.2010;
RA   Rozengurt E.;
RT   "Protein kinase D signaling: multiple biological functions in health
RT   and disease.";
RL   Physiology (Bethesda) 26:23-33(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205 AND SER-208, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [28]
RP   FUNCTION, INTERACTION WITH USP28, AND INDUCTION.
RX   PubMed=24623306; DOI=10.7554/eLife.02313;
RA   Serra R.W., Fang M., Park S.M., Hutchinson L., Green M.R.;
RT   "A KRAS-directed transcriptional silencing pathway that mediates the
RT   CpG island methylator phenotype.";
RL   Elife 3:E02313-E02313(2014).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-152 AND LYS-857.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-225; GLN-478; SER-585; MET-677;
RP   LEU-679 AND ARG-891.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that converts transient
CC       diacylglycerol (DAG) signals into prolonged physiological effects
CC       downstream of PKC, and is involved in the regulation of MAPK8/JNK1
CC       and Ras signaling, Golgi membrane integrity and trafficking, cell
CC       survival through NF-kappa-B activation, cell migration, cell
CC       differentiation by mediating HDAC7 nuclear export, cell
CC       proliferation via MAPK1/3 (ERK1/2) signaling, and plays a role in
CC       cardiac hypertrophy, VEGFA-induced angiogenesis, genotoxic-induced
CC       apoptosis and flagellin-stimulated inflammatory response.
CC       Phosphorylates the epidermal growth factor receptor (EGFR) on dual
CC       threonine residues, which leads to the suppression of epidermal
CC       growth factor (EGF)-induced MAPK8/JNK1 activation and subsequent
CC       JUN phosphorylation. Phosphorylates RIN1, inducing RIN1 binding to
CC       14-3-3 proteins YWHAB, YWHAE and YWHAZ and increased competition
CC       with RAF1 for binding to GTP-bound form of Ras proteins (NRAS,
CC       HRAS and KRAS). Acts downstream of the heterotrimeric G-protein
CC       beta/gamma-subunit complex to maintain the structural integrity of
CC       the Golgi membranes, and is required for protein transport along
CC       the secretory pathway. In the trans-Golgi network (TGN), regulates
CC       the fission of transport vesicles that are on their way to the
CC       plasma membrane. May act by activating the lipid kinase
CC       phosphatidylinositol 4-kinase beta (PI4KB) at the TGN for the
CC       local synthesis of phosphorylated inositol lipids, which induces a
CC       sequential production of DAG, phosphatidic acid (PA) and lyso-PA
CC       (LPA) that are necessary for membrane fission and generation of
CC       specific transport carriers to the cell surface. Under oxidative
CC       stress, is phosphorylated at Tyr-463 via SRC-ABL1 and contributes
CC       to cell survival by activating IKK complex and subsequent nuclear
CC       translocation and activation of NFKB1. Involved in cell migration
CC       by regulating integrin alpha-5/beta-3 recycling and promoting its
CC       recruitment in newly forming focal adhesion. In osteoblast
CC       differentiation, mediates the bone morphogenetic protein 2 (BMP2)-
CC       induced nuclear export of HDAC7, which results in the inhibition
CC       of HDAC7 transcriptional repression of RUNX2. In neurons, plays an
CC       important role in neuronal polarity by regulating the biogenesis
CC       of TGN-derived dendritic vesicles, and is involved in the
CC       maintenance of dendritic arborization and Golgi structure in
CC       hippocampal cells. May potentiate mitogenesis induced by the
CC       neuropeptide bombesin or vasopressin by mediating an increase in
CC       the duration of MAPK1/3 (ERK1/2) signaling, which leads to
CC       accumulation of immediate-early gene products including FOS that
CC       stimulate cell cycle progression. Plays an important role in the
CC       proliferative response induced by low calcium in keratinocytes,
CC       through sustained activation of MAPK1/3 (ERK1/2) pathway.
CC       Downstream of novel PKC signaling, plays a role in cardiac
CC       hypertrophy by phosphorylating HDAC5, which in turn triggers
CC       XPO1/CRM1-dependent nuclear export of HDAC5, MEF2A transcriptional
CC       activation and induction of downstream target genes that promote
CC       myocyte hypertrophy and pathological cardiac remodeling. Mediates
CC       cardiac troponin I (TNNI3) phosphorylation at the PKA sites, which
CC       results in reduced myofilament calcium sensitivity, and
CC       accelerated crossbridge cycling kinetics. The PRKD1-HDAC5 pathway
CC       is also involved in angiogenesis by mediating VEGFA-induced
CC       specific subset of gene expression, cell migration, and tube
CC       formation. In response to VEGFA, is necessary and required for
CC       HDAC7 phosphorylation which induces HDAC7 nuclear export and
CC       endothelial cell proliferation and migration. During apoptosis
CC       induced by cytarabine and other genotoxic agents, PRKD1 is cleaved
CC       by caspase-3 at Asp-378, resulting in activation of its kinase
CC       function and increased sensitivity of cells to the cytotoxic
CC       effects of genotoxic agents. In epithelial cells, is required for
CC       transducing flagellin-stimulated inflammatory responses by binding
CC       and phosphorylating TLR5, which contributes to MAPK14/p38
CC       activation and production of inflammatory cytokines. May play a
CC       role in inflammatory response by mediating activation of NF-kappa-
CC       B. May be involved in pain transmission by directly modulating
CC       TRPV1 receptor. Plays a role in activated KRAS-mediated
CC       stabilization of ZNF304 in colorectal cancer (CRC) cells
CC       (PubMed:24623306). Regulates nuclear translocation of
CC       transcription factor TFEB in macrophages upon live S.enterica
CC       infection (By similarity). {ECO:0000250|UniProtKB:Q62101,
CC       ECO:0000269|PubMed:10523301, ECO:0000269|PubMed:10764790,
CC       ECO:0000269|PubMed:12505989, ECO:0000269|PubMed:12637538,
CC       ECO:0000269|PubMed:15471852, ECO:0000269|PubMed:17442957,
CC       ECO:0000269|PubMed:18332134, ECO:0000269|PubMed:18509061,
CC       ECO:0000269|PubMed:19135240, ECO:0000269|PubMed:19211839,
CC       ECO:0000269|PubMed:24623306}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by DAG and phorbol esters. Phorbol-
CC       ester/DAG-type domain 1 binds DAG with high affinity and appears
CC       to play the dominant role in mediating translocation to the cell
CC       membrane and trans-Golgi network. Phorbol-ester/DAG-type domain 2
CC       binds phorbol ester with higher affinity. Autophosphorylation of
CC       Ser-742 and phosphorylation of Ser-738 by PKC relieves auto-
CC       inhibition by the PH domain. Phosphorylation on Tyr-463 by the
CC       SRC-ABL1 pathway in response to oxidative stress, is also required
CC       for activation. Activated by DAPK1 under oxidative stress.
CC       {ECO:0000269|PubMed:12637538, ECO:0000269|PubMed:17703233,
CC       ECO:0000269|PubMed:18076381}.
CC   -!- SUBUNIT: Interacts (via N-terminus) with ADAP1/CENTA1
CC       (PubMed:12893243). Interacts with MAPK13 (PubMed:19135240).
CC       Interacts with DAPK1 in an oxidative stress-regulated manner
CC       (PubMed:17703233). Interacts with USP28; the interaction induces
CC       phosphorylation of USP28 and activated KRAS-mediated stabilization
CC       of ZNF304 (PubMed:24623306). Interacts with AKAP13 (via C-terminal
CC       domain) (By similarity). {ECO:0000250|UniProtKB:Q62101,
CC       ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:17703233,
CC       ECO:0000269|PubMed:19135240, ECO:0000269|PubMed:24623306}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-1181072, EBI-1181072;
CC       Q07021:C1QBP; NbExp=9; IntAct=EBI-1181072, EBI-347528;
CC       P12830:CDH1; NbExp=7; IntAct=EBI-1181072, EBI-727477;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-1181072, EBI-352572;
CC       O15264:MAPK13; NbExp=6; IntAct=EBI-1181072, EBI-2116951;
CC       P02795:MT2A; NbExp=7; IntAct=EBI-1181072, EBI-996616;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18076381}.
CC       Cell membrane {ECO:0000269|PubMed:18076381}. Golgi apparatus,
CC       trans-Golgi network {ECO:0000250|UniProtKB:Q62101}.
CC       Note=Translocation to the cell membrane is required for kinase
CC       activation.
CC   -!- INDUCTION: Up-regulated by the intestine-specific transcription
CC       factor CDX1 in a activated KRAS-dependent manner in colorectal
CC       cancer (CRC) cells (PubMed:24623306).
CC       {ECO:0000269|PubMed:24623306}.
CC   -!- PTM: Phosphorylated at Ser-397 and Ser-401 by MAPK13 during
CC       regulation of insulin secretion in pancreatic beta cells
CC       (PubMed:19135240). Phosphorylated by DAPK1 (PubMed:17703233).
CC       Phosphorylated at Tyr-95 and by ABL at Tyr-463, which primes the
CC       kinase in response to oxidative stress, and promotes a second step
CC       activating phosphorylation at Ser-738/Ser-742 by PKRD
CC       (PubMed:12637538, PubMed:15024053, PubMed:17804414).
CC       Phosphorylated on Ser-910 upon S.enterica infection in macrophages
CC       (By similarity). {ECO:0000250|UniProtKB:Q62101,
CC       ECO:0000269|PubMed:12637538, ECO:0000269|PubMed:15024053,
CC       ECO:0000269|PubMed:17703233, ECO:0000269|PubMed:17804414,
CC       ECO:0000269|PubMed:19135240}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. PKD subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PRKCMID41860ch14q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X75756; CAA53384.1; -; mRNA.
DR   EMBL; AK314170; BAG36853.1; -; mRNA.
DR   EMBL; AL135858; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471078; EAW65971.1; -; Genomic_DNA.
DR   CCDS; CCDS9637.1; -.
DR   PIR; A53215; A53215.
DR   RefSeq; NP_002733.2; NM_002742.2.
DR   UniGene; Hs.508999; -.
DR   ProteinModelPortal; Q15139; -.
DR   SMR; Q15139; -.
DR   BioGrid; 111573; 31.
DR   DIP; DIP-38481N; -.
DR   IntAct; Q15139; 7.
DR   MINT; MINT-88491; -.
DR   STRING; 9606.ENSP00000333568; -.
DR   BindingDB; Q15139; -.
DR   ChEMBL; CHEMBL3863; -.
DR   GuidetoPHARMACOLOGY; 1489; -.
DR   iPTMnet; Q15139; -.
DR   PhosphoSitePlus; Q15139; -.
DR   BioMuta; PRKD1; -.
DR   DMDM; 209572639; -.
DR   EPD; Q15139; -.
DR   MaxQB; Q15139; -.
DR   PaxDb; Q15139; -.
DR   PeptideAtlas; Q15139; -.
DR   PRIDE; Q15139; -.
DR   DNASU; 5587; -.
DR   Ensembl; ENST00000331968; ENSP00000333568; ENSG00000184304.
DR   Ensembl; ENST00000616995; ENSP00000482645; ENSG00000184304.
DR   GeneID; 5587; -.
DR   KEGG; hsa:5587; -.
DR   UCSC; uc001wqh.4; human.
DR   CTD; 5587; -.
DR   DisGeNET; 5587; -.
DR   GeneCards; PRKD1; -.
DR   H-InvDB; HIX0037727; -.
DR   HGNC; HGNC:9407; PRKD1.
DR   HPA; CAB018367; -.
DR   HPA; HPA029834; -.
DR   MalaCards; PRKD1; -.
DR   MIM; 605435; gene.
DR   neXtProt; NX_Q15139; -.
DR   OpenTargets; ENSG00000184304; -.
DR   PharmGKB; PA33771; -.
DR   eggNOG; KOG4236; Eukaryota.
DR   eggNOG; ENOG410XQZ3; LUCA.
DR   GeneTree; ENSGT00840000129794; -.
DR   HOVERGEN; HBG003564; -.
DR   InParanoid; Q15139; -.
DR   KO; K06070; -.
DR   PhylomeDB; Q15139; -.
DR   TreeFam; TF314320; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   SignaLink; Q15139; -.
DR   SIGNOR; Q15139; -.
DR   ChiTaRS; PRKD1; human.
DR   GeneWiki; Protein_kinase_D1; -.
DR   GenomeRNAi; 5587; -.
DR   PRO; PR:Q15139; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000184304; -.
DR   CleanEx; HS_PKD1; -.
DR   CleanEx; HS_PRKD1; -.
DR   ExpressionAtlas; Q15139; baseline and differential.
DR   Genevisible; Q15139; HS.
DR   GO; GO:0000421; C:autophagosome membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:CACAO.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004697; F:protein kinase C activity; IDA:CACAO.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0071447; P:cellular response to hydroperoxide; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProtKB.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IMP:UniProtKB.
DR   GO; GO:0007030; P:Golgi organization; IMP:UniProtKB.
DR   GO; GO:0048193; P:Golgi vesicle transport; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IMP:BHF-UCL.
DR   GO; GO:0060548; P:negative regulation of cell death; IMP:UniProtKB.
DR   GO; GO:0045806; P:negative regulation of endocytosis; TAS:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; IGI:BHF-UCL.
DR   GO; GO:2001028; P:positive regulation of endothelial cell chemotaxis; IMP:BHF-UCL.
DR   GO; GO:0038033; P:positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IGI:BHF-UCL.
DR   GO; GO:1901727; P:positive regulation of histone deacetylase activity; IGI:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IGI:BHF-UCL.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IC:ParkinsonsUK-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0089700; P:protein kinase D signaling; IGI:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IMP:UniProtKB.
DR   GO; GO:2001044; P:regulation of integrin-mediated signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0010837; P:regulation of keratinocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   CDD; cd00029; C1; 2.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015727; Protein_Kinase_C_mu-related.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR22968; PTHR22968; 1.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF000552; PKC_mu_nu_D2; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   Angiogenesis; Apoptosis; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Differentiation; Golgi apparatus;
KW   Immunity; Inflammatory response; Innate immunity; Kinase; Magnesium;
KW   Membrane; Metal-binding; Neurogenesis; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN         1    912       Serine/threonine-protein kinase D1.
FT                                /FTId=PRO_0000055714.
FT   DOMAIN      422    541       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      583    839       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING     146    196       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     270    320       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     589    597       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS     17     26       Poly-Ala.
FT   COMPBIAS    200    203       Poly-Arg.
FT   ACT_SITE    706    706       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     612    612       ATP.
FT   MOD_RES      95     95       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:17804414}.
FT   MOD_RES     205    205       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     208    208       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     345    345       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     397    397       Phosphoserine; by MAPK13.
FT                                {ECO:0000269|PubMed:19135240}.
FT   MOD_RES     401    401       Phosphoserine; by MAPK13.
FT                                {ECO:0000269|PubMed:19135240}.
FT   MOD_RES     432    432       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12637538}.
FT   MOD_RES     448    448       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     463    463       Phosphotyrosine; by ABL.
FT                                {ECO:0000269|PubMed:12637538,
FT                                ECO:0000269|PubMed:15024053}.
FT   MOD_RES     473    473       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     502    502       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12637538}.
FT   MOD_RES     738    738       Phosphoserine; by PKC/PRKCD.
FT                                {ECO:0000269|PubMed:15024053}.
FT   MOD_RES     742    742       Phosphoserine; by autocatalysis and
FT                                PKC/PRKCD. {ECO:0000269|PubMed:15024053}.
FT   MOD_RES     910    910       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17703233}.
FT   VARIANT     152    152       H -> Y (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035468.
FT   VARIANT     225    225       S -> P. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042324.
FT   VARIANT     478    478       K -> Q (in dbSNP:rs55852813).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042325.
FT   VARIANT     585    585       P -> S (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042326.
FT   VARIANT     677    677       R -> M (in a lung bronchoalveolar
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042327.
FT   VARIANT     679    679       P -> L (in dbSNP:rs34588699).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042328.
FT   VARIANT     825    825       R -> K (in dbSNP:rs11161065).
FT                                /FTId=VAR_046988.
FT   VARIANT     857    857       E -> K (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035469.
FT   VARIANT     891    891       H -> R (in dbSNP:rs45582934).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042329.
FT   MUTAGEN     157    157       P->G: Increase in ability to bind phorbol
FT                                ester, loss of ability to bind DAG.
FT                                {ECO:0000269|PubMed:18076381}.
FT   MUTAGEN     281    281       P->G: No effect on ability to bind
FT                                phorbol ester, slight increase in ability
FT                                to bind DAG.
FT                                {ECO:0000269|PubMed:18076381}.
FT   MUTAGEN     432    432       Y->E: Decreased phosphorylation level
FT                                when coexpressed with SRC in HeLa cells.
FT                                Unchanged phosphorylation level when
FT                                coexpressed with ABL.
FT                                {ECO:0000269|PubMed:12637538}.
FT   MUTAGEN     432    432       Y->F: Decreased phosphorylation level
FT                                when coexpressed with SRC in HeLa cells.
FT                                Unchanged phosphorylation level when
FT                                coexpressed with ABL. Unaltered kinase
FT                                activity. Decreased kinase activity; when
FT                                associated with F-463 and F-502.
FT                                {ECO:0000269|PubMed:12637538}.
FT   MUTAGEN     463    463       Y->E: Constitutive activation and
FT                                constitutive phosphorylation of S-738 and
FT                                S-742. {ECO:0000269|PubMed:12637538}.
FT   MUTAGEN     463    463       Y->F: Decreased phosphorylation level
FT                                when coexpressed with either SRC or ABL
FT                                in HeLa cells. Decreased kinase activity.
FT                                {ECO:0000269|PubMed:12637538}.
FT   MUTAGEN     502    502       Y->E: Loss of activation.
FT                                {ECO:0000269|PubMed:12637538}.
FT   MUTAGEN     502    502       Y->F: Decreased phosphorylation level
FT                                when coexpressed with SRC in HeLa cells.
FT                                Unchanged phosphorylation level when
FT                                coexpressed with ABL. Unaltered kinase
FT                                activity. Decreased kinase activity; when
FT                                associated with F-432 and F-502.
FT                                {ECO:0000269|PubMed:12637538}.
FT   MUTAGEN     612    612       K->W: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:12637538}.
FT   CONFLICT    135    135       A -> R (in Ref. 1; CAA53384).
FT                                {ECO:0000305}.
FT   CONFLICT    877    877       G -> R (in Ref. 1; CAA53384).
FT                                {ECO:0000305}.
SQ   SEQUENCE   912 AA;  101704 MW;  0BC9414C335D2DBB CRC64;
     MSAPPVLRPP SPLLPVAAAA AAAAAALVPG SGPGPAPFLA PVAAPVGGIS FHLQIGLSRE
     PVLLLQDSSG DYSLAHVREM ACSIVDQKFP ECGFYGMYDK ILLFRHDPTS ENILQLVKAA
     SDIQEGDLIE VVLSASATFE DFQIRPHALF VHSYRAPAFC DHCGEMLWGL VRQGLKCEGC
     GLNYHKRCAF KIPNNCSGVR RRRLSNVSLT GVSTIRTSSA ELSTSAPDEP LLQKSPSESF
     IGREKRSNSQ SYIGRPIHLD KILMSKVKVP HTFVIHSYTR PTVCQYCKKL LKGLFRQGLQ
     CKDCRFNCHK RCAPKVPNNC LGEVTINGDL LSPGAESDVV MEEGSDDNDS ERNSGLMDDM
     EEAMVQDAEM AMAECQNDSG EMQDPDPDHE DANRTISPST SNNIPLMRVV QSVKHTKRKS
     STVMKEGWMV HYTSKDTLRK RHYWRLDSKC ITLFQNDTGS RYYKEIPLSE ILSLEPVKTS
     ALIPNGANPH CFEITTANVV YYVGENVVNP SSPSPNNSVL TSGVGADVAR MWEIAIQHAL
     MPVIPKGSSV GTGTNLHRDI SVSISVSNCQ IQENVDISTV YQIFPDEVLG SGQFGIVYGG
     KHRKTGRDVA IKIIDKLRFP TKQESQLRNE VAILQNLHHP GVVNLECMFE TPERVFVVME
     KLHGDMLEMI LSSEKGRLPE HITKFLITQI LVALRHLHFK NIVHCDLKPE NVLLASADPF
     PQVKLCDFGF ARIIGEKSFR RSVVGTPAYL APEVLRNKGY NRSLDMWSVG VIIYVSLSGT
     FPFNEDEDIH DQIQNAAFMY PPNPWKEISH EAIDLINNLL QVKMRKRYSV DKTLSHPWLQ
     DYQTWLDLRE LECKIGERYI THESDDLRWE KYAGEQGLQY PTHLINPSAS HSDTPETEET
     EMKALGERVS IL
//
